PTJ
AVBP icon

Paul Tudor Jones’s ArriVent BioPharma AVBP Stock Holding History

Paul Tudor Jones’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$809K Buy
23,287
+1,186
+5% +$35K ﹤0.01% 2561
2026
Q1 		$510K Buy
+22,101
New +$499K ﹤0.01% 2803
2025
Q2 		– Sell
-15,293
Closed -$283K – 3853
2025
Q1 		$283K Buy
+15,293
New +$374K ﹤0.01% 2633

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's AVBP Position: Q2 2026 in Review

Paul Tudor Jones increased its ArriVent BioPharma (AVBP) stake by 5.4% in Q2 2026, buying an estimated $35K and bringing the position to 23,287 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #2561.

Paul Tudor Jones first reported a position in AVBP in Q1 2025 and has held it in 3 quarters since. 156 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Paul Tudor Jones held 23,287 shares of ArriVent BioPharma worth $809K as of Q2 2026.
  • Paul Tudor Jones bought 1,186 ArriVent BioPharma shares in Q2 2026, an estimated $35K.
  • ArriVent BioPharma made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2561 holding.
  • Paul Tudor Jones first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 3 quarters since.
  • 156 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.